Illumina, Inc. (NASDAQ:ILMN) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 28.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 18,082 shares of the life sciences company’s stock after selling 7,345 shares during the period. State of Alaska Department of Revenue’s holdings in Illumina were worth $2,416,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Geode Capital Management LLC raised its holdings in Illumina by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after buying an additional 48,018 shares during the period. Primecap Management Co. CA raised its holdings in Illumina by 3.6% in the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after buying an additional 87,599 shares during the period. Janus Henderson Group PLC raised its holdings in Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after buying an additional 625,245 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Illumina by 4.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock valued at $164,334,000 after buying an additional 54,319 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its holdings in Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after buying an additional 631,294 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

ILMN stock opened at $104.99 on Tuesday. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66. The firm has a market capitalization of $16.65 billion, a PE ratio of -13.67 and a beta of 1.10. The firm has a 50-day moving average of $136.70 and a two-hundred day moving average of $135.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. On average, analysts forecast that Illumina, Inc. will post 4.42 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. UBS Group lifted their price objective on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective on the stock in a research note on Thursday, October 17th. Barclays lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $130.00 to $100.00 in a research note on Monday. JPMorgan Chase & Co. lifted their price objective on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and dropped their price objective for the company from $177.00 to $140.00 in a research note on Friday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average target price of $160.15.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.